Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lakewood-Amedex Biotherapeutics Inc. (LABT : NSDQ)

• Company Description    Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin(R) class. Lakewood-Amedex Biotherapeutics Inc. is based in SARASOTA, Fla. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $2.18 Daily Weekly Monthly 20 Day Moving Average: 1,018,741 shares Shares Outstanding: 2.37 (millions) Market Capitalization: $5.17 (millions) Beta: 52 Week High: $98.20 52 Week Low: $1.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.63% -6.97% 12 Week -70.30% -70.93% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8031 COOPER CREEK BLVD. SUITE 103 - UNIVERSITY PARK,FL 34201 USA ph: 941-225-2515 fax: - dirish@tiberend.com https://lakewoodamedex.com

• General Corporate Information    Officers Kelvin Cooper - Chief Executive Officer Doug Manion - Chairman of the Board PeterCeccacci - Chief Financial Officer Leonard J.DeRoma - Director Joseph Tucker - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 51255A201 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 2.37 Most Recent Split Date: 6.00 (0.10:1) Beta: Market Capitalization: $5.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.81 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $4.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: 0.44 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.19 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -37.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - 7.70 03/31/26 - 0.02 12/31/25 - 0.13 Quick Ratio 06/30/26 - 7.70 03/31/26 - 0.02 12/31/25 - 0.13 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 1.83 03/31/26 - -4.07 12/31/25 - - Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - 0.00 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©